Thierry Lesimple
Overview
Explore the profile of Thierry Lesimple including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
2359
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Benguerfi S, Lesimple T, Houot R, Ricordel C, Legoupil D, Alleaume C, et al.
Acta Oncol
. 2022 Oct;
61(11):1339-1346.
PMID: 36239950
Background: Data regarding characteristics, safety and survival outcomes of patients aged 80 or older treated with immune checkpoint inhibitors (ICI) in routine oncology practice are limited. Materials And Methods: We...
12.
Dutriaux C, Robert C, Grob J, Mortier L, Dereure O, Lebbe C, et al.
Eur J Cancer
. 2022 Sep;
175:254-262.
PMID: 36170791
Background: Despite the poor prognosis associated with melanoma brain metastases (BM), data concerning these patients and their inclusion in clinical trials remains scarce. We report here the efficacy results of...
13.
Marce D, Vilain-Abraham F, Bridou M, Quereux G, Dupuy A, Lesimple T, et al.
Cancers (Basel)
. 2022 Aug;
14(16).
PMID: 36010858
Background: First-degree relatives (FDRs, defined as parents, children, and siblings) of melanoma patients are at a two-to-fivefold increased risk of developing melanoma themselves. FDRs are advised to perform self-skin examination...
14.
Saint-Ghislain M, Derrien A, Geoffrois L, Gastaud L, Lesimple T, Negrier S, et al.
Eur J Cancer
. 2022 Jul;
173:105-112.
PMID: 35863105
Background: MBD4 mutations have been reported in uveal melanomas, acute myeloid leukemias, colorectal adenocarcinomas, gliomas, and spiradenocarcinomas and cause a hypermutated phenotype. Although metastatic uveal melanomas (mUM) are usually resistant...
15.
Bhave P, Ahmed T, Lo S, Shoushtari A, Zaremba A, Versluis J, et al.
J Immunother Cancer
. 2022 Jul;
10(7).
PMID: 35793872
Background: Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the...
16.
Placais L, Dalle S, Dereure O, Trabelsi S, Dalac S, Legoupil D, et al.
Ann Rheum Dis
. 2022 Jul;
81(10):1445-1452.
PMID: 35788496
Objective: To quantify the risk of immune-related adverse events (irAEs) in patients with pre-existing autoimmune disease (pAID) treated by immune checkpoint inhibitors (ICIs) for stage III or IV melanoma. Methods:...
17.
Poizeau F, Kerbrat S, Balusson F, Tattevin P, Revest M, Cattoir V, et al.
J Natl Cancer Inst
. 2022 Mar;
114(5):686-694.
PMID: 35253890
Background: Several observational studies have reported a decreased response to immune checkpoint inhibitors (ICI) following antibiotic use. ICI activity has been hypothesized to be impaired by antibiotic-induced gut dysbiosis. Methods:...
18.
Saiag P, Robert C, Grob J, Mortier L, Dereure O, Lebbe C, et al.
Eur J Cancer
. 2021 Jul;
154:57-65.
PMID: 34243078
Background: BRAF and MEK inhibitors combination, including dabrafenib (D) and trametinib (T) have transformed the treatment of BRAF V600-mutant advanced melanoma patients, including patients with brain metastasis (BM). In a...
19.
Becquart O, Oriano B, Dalle S, Mortier L, Leccia M, Dutriaux C, et al.
Cancers (Basel)
. 2021 Jul;
13(12).
PMID: 34207200
Purpose: Melanoma's incidence is increasing, and elderly people could be significantly impacted since the majority occurs in people over 65 years of age. Combined BRAF and MEK targeted therapies (TT)...
20.
van den Bent M, Tesileanu C, Wick W, Sanson M, Brandes A, Clement P, et al.
Lancet Oncol
. 2021 May;
22(6):813-823.
PMID: 34000245
Background: The CATNON trial investigated the addition of concurrent, adjuvant, and both current and adjuvant temozolomide to radiotherapy in adults with newly diagnosed 1p/19q non-co-deleted anaplastic gliomas. The benefit of...